The minister also added that apart from pandemic and health emergencies, there is an ample scope of collaboration among countries like in the field of vaccine preventable diseases with high morbidity and mortality and for those diseases with no vaccines available currently such as AIDS, TB, etc.
In an application sent to the DCGI on February 9, Srinivas Kosaraju, the head of Quality and Regulatory Affairs of Biological E Limited said the firm had received approval for conducting phase 2/3 clinical study of Corbevax among children and adolescents aged 5-18 years in September.
The court's three liberal justices dissented from the ruling. "When we are wise, we know not to displace the judgments of experts, acting within the sphere Congress marked out and under Presidential control, to deal with emergency conditions," they wrote in the dissenting opinion.
AstraZeneca said this data adds to the growing body of evidence supporting Vaxzevria as a third dose booster, irrespective of the primary vaccination schedules tested.
COVAXIN Booster Dose Data Shows Promising Results
The feature of online appointment for precautionary dose was made operational on the CoWIN portal on Saturday late night. Those eligible to receive precaution dose of Covid vaccines can book online appointment.
The decision came as the Omicron variant is spreading rapidly across the US and has led to record high hospitalisations among younger people.
With the drive starting mostly from schools, many principals and other officials said they received a positive response from students and their families.
The Indian Council of Medical Research also said recently that all Covid vaccines do not prevent infection and are primarily disease-modifying.
WHO Director General issues Strategic Advisory Group of Experts on Immunization’s (SAGE) interim statement on booster doses.
India on Thursday registered 7,495 fresh Covid cases and 434 deaths in a span of 24 hours.
To a query related to Omicron, he said that studies are going on and only after the studies are complete, it will be known which vaccine is how much effective against the new variant.
Meanwhile top US infectious disease expert Anthony Fauci said that early data on the Omicron Covid-19 variant is a "bit encouraging" and does not indicate a great degree of danger, says.
In addition, a significantly higher number of short-lived vaccine reactions were reported in volunteers who received a second dose of Moderna compared to those who received two doses of either AstraZeneca or Pfizer.
The study provides comprehensive data on the real-world vaccine effectiveness and immunological response to vaccination which should help guide policy. The study thus implies that the vaccines continued to be effective in protecting against severe disease and death regardless of the variants.
Justice Chandrachud emphasized, "When you have guidelines, why should the court interfere at this crucial stage of vaccination? Every country in the world has multiple vaccines...look at the developed world, the US."
The Union ministry of health and family welfare said earlier that nearly 100 countries have agreed to the mutual acceptance of vaccination certificates of India's Covid-19 vaccines and the vaccination process.
The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said.
An analysis reveals that Odisha has very fewer vaccination sites to inoculate its eligible population. Chhattisgarh and Assam have opened 4,300 and 3,489 vaccination sites, respectively, against a mere 2,194 in Odisha
Citing the reasons for booster dose in the US, he said that the Delta variant is causing infections in European countries and that is also a reason for booster dose there. However, India has passed that phase now. "Healthcare workers were the first to be vaccinated. But no case has yet come after around 9 to 10 months which can advocate the need for the booster doses in India", opined Dr Seth.